Relmada Therapeutics Inc (NAS:RLMD)
$ 4.54 -0.41 (-8.28%) Market Cap: 484.28 Mil Enterprise Value: 266.55 Mil PE Ratio: 0 PB Ratio: 2.17 GF Score: 29/100

Q3 2022 Relmada Therapeutics Inc Earnings Call Transcript

Nov 10, 2022 / 09:30 PM GMT
Release Date Price: $5.84 (+1.39%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

RLMD.OQ - Relmada Therapeutics Inc
Q3 2022 Relmada Therapeutics Inc Earnings Call
Nov 10, 2022 / 09:30PM GMT

=====================
Conference Call Participants
=====================
* >>Brian Ritchie - LifeSci Advisors, LLC
* >>Sergio Traversa - CEO
* >>Maged Shenouda - CFO
* >>Maurizio Fava
* >>Guofang Li - SVB Securities LLC, Research Division
* >>Yatin Suneja - Guggenheim Securities, LLC, Research Division
* >>Andrea Tan - Goldman Sachs Group, Inc., Research Division
* >>Lin Tsai - Jefferies LLC, Research Division
* >>Jay Olson - Oppenheimer & Co. Inc., Research Division
* >>Joon So Lee - Truist Securities, Inc., Research Division

=====================
Presentation
--------------------------------------------------------------------------------
Operator [1]
--------------------------------------------------------------------------------

Good afternoon. My name is Kathy, and I'll
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot